Compare BridgeBio Pharma Inc (BBIO) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Microchip Technology Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Microchip Technology Inc. trades at $81.48 (market cap $44.20B). The key difference: Microchip Technology Inc. is far larger — about 2.7× BridgeBio Pharma Inc's market cap, and Microchip Technology Inc. pays a 2.24% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MCHP | |
|---|---|---|
Market Cap | $16.61B | $44.20B |
Sector | Health | Technology |
52-Week High | $90.17 | $102.97 |
52-Week Low | $47.29 | $49.02 |
Enterprise Value | $18.16B | $49.32B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Microchip Technology (MCHP) trades at $84.69, up 13.89% in 24 hours, reflecting strong momentum. The stock is in a bullish technical trend, with recent earnings beats and robust data center revenue growth of 98% last quarter. Analyst consensus is strongly bullish with a $104 price target. However, valuation ratios like a P/E of 124.54 are elevated, and 2025 net income was negative, posing fundamental concerns despite a recovery forecast for 2026.
Outlook is positive driven by AI and data center demand, but high valuation and past profitability volatility are risks. The stock offers growth exposure amid analyst optimism, yet investors should weigh premium pricing against execution risks in a competitive semiconductor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
